99. 慢性特発性偽性腸閉塞症 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 7 / 薬物数 : 10 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
Fecal microbiota transplantation
   Jinling Hospital, China
      2014   -   NCT02731183   China
PLA-PRU-PLA-PRU
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom
PLA-PRU-PRU-PLA
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom
PRU-PLA-PLA-PRU
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom
PRU-PLA-PRU-PLA
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom
Rifaximin
   Ohkubo Hidenori
      2019   Phase 2   JPRN-jRCT2031190137   -
Rifaximin oral tablet
   Yokohama City University
      2019   Phase 2   NCT04118699   Japan
Sequential fecal microbiota transplant combined with small intestinal fluid transplant
   Shanghai 10th People's Hospital
      2018   -   NCT06020365   China
THRX-199687 hydrochloride
   ALFASIGMA S.P.A.
      2022   Phase 2   EUCTR2021-000854-24-BE   Belgium;Italy;Spain
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain
Velusetrag
   ALFASIGMA S.P.A.
      2022   Phase 2   EUCTR2021-000854-24-BE   Belgium;Italy;Spain
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain